Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy

Gene Therapy volume 11, pages 874–878 (2004)Cite this article

Abstract

Ovarian carcinoma cells are often infected inefficiently by adenoviruses (Ad) due to low expression of coxsackie–adenovirus receptors (CAR), hindering the application of adenovirus-mediated gene therapy in ovarian cancer. In this study, we explored a class of infectivity-enhanced Ad vectors, which contain CAR-independent targeting motifs RGD (Ad5.RGD), polylysine (Ad5.pK7), or both (Ad5.RGD.pK7), for their utility in ovarian cancer gene therapy using in vitro and in vivo model systems. We found that these vectors infected established ovarian carcinoma cell lines and primary ovarian cancer cells with significantly enhanced infectivity. Among them, Ad5.RGD.pK7 appeared to be most efficient. Further, we evaluated their gene delivery efficiency using two different ovarian cancer mouse models – subcutaneous and intraperitoneal human ovarian cancer xenografts. All of the modified vectors appeared to be more efficient than the unmodified Ad5 vector in both models, although some of the differences are not statistically significant. Of these, Ad5.RGD.pK7 exhibited the highest efficacy in the subcutaneous tumor model, while Ad5.pK7 worked most efficiently in the intraperitoneal tumor model. These preclinical results suggest that Ad5.RGD.pK7 and Ad5.pK7 may be very useful in ovarian cancer gene therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Vasey PA et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562–1569.

    CAS  PubMed  Google Scholar 

  2. Wen SF et al. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther 2003; 10: 224–238.

    Article  CAS  PubMed  Google Scholar 

  3. Zabner J et al. Lack of high affinity fiber receptor activity explains the resistance of ciliated airway epithelia to adenovirus infection. J Clin Invest 1997; 100: 1144–1149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Li Y et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325–330.

    CAS  PubMed  Google Scholar 

  5. Zeimet AG et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Therapy 2002; 9: 1093–1100.

    Article  CAS  PubMed  Google Scholar 

  6. Michael SI, Hong JS, Curiel DT, Engler JA . Addition of a short peptide ligand to the adenovirus fiber protein. Gene Therapy 1995; 2: 660–668.

    CAS  PubMed  Google Scholar 

  7. Wickham TJ, Roelvink PW, Brough DE, Kovesdi I . Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14: 1570–1573.

    Article  CAS  PubMed  Google Scholar 

  8. Wickham TJ et al. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol 1997; 71: 8221–8229.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Dmitriev I et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706–9713.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Krasnykh V et al. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol 1998; 72: 1844–1852.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Wu H et al. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus–adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 2002; 13: 1647–1653.

    Article  CAS  PubMed  Google Scholar 

  12. Koizumi N et al. Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J Gene Med 2003; 5: 267–276.

    Article  CAS  PubMed  Google Scholar 

  13. Marshall JF, Hart IR . The role of alpha v-integrins in tumour progression and metastasis. Semin Cancer Biol 1996; 7: 129–138.

    Article  CAS  PubMed  Google Scholar 

  14. Kerr JS, Slee AM, Mousa SA . Small molecule alpha(v) integrin antagonists: novel anticancer agents. Expert Opin Investig Drugs 2000; 9: 1271–1279.

    Article  CAS  PubMed  Google Scholar 

  15. Blackhall FH, Merry CL, Davies EJ, Jayson GC . Heparan sulfate proteoglycans and cancer. Br J Cancer 2001; 85: 1094–1098.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Sanderson RD . Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 2001; 12: 89–98.

    Article  CAS  PubMed  Google Scholar 

  17. Yamaguchi Y . Heparan sulfate proteoglycans in the nervous system: their diverse roles in neurogenesis, axon guidance, and synaptogenesis. Semin Cell Dev Biol 2001; 12: 99–106.

    Article  CAS  PubMed  Google Scholar 

  18. Shriver Z, Liu D, Sasisekharan R . Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc Med 2002; 12: 71–77.

    Article  CAS  PubMed  Google Scholar 

  19. Contreras JL et al. Double genetic modification of adenovirus fiber with RGD and polylysine motifs significantly enhances gene transfer to isolated human pancreatic islets. Transplantation 2003; 76: 252–261.

    Article  CAS  PubMed  Google Scholar 

  20. Barker SD et al. An immunomagnetic-based method for the purification of ovarian cancer cells from patient-derived ascites. Gynecol Oncol 2001; 82: 57–63.

    Article  CAS  PubMed  Google Scholar 

  21. Kanerva A et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695–704.

    Article  CAS  PubMed  Google Scholar 

  22. Staba M-J, Wickham TJ, Kovesdi I, Hallahan DE . Modification of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther 2000; 7: 13–19.

    Article  CAS  PubMed  Google Scholar 

  23. Thomas CE et al. Adenovirus binding to the coxsackievirus and adenovirus receptor or integrins is not required to elicit brain inflammation but is necessary to transduce specific neural cell types. J Virol 2002; 76: 3452–3460.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bauerschmitz GJ et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266–1270.

    CAS  PubMed  Google Scholar 

  25. Hemminki A et al. In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst 2002; 94: 741–749.

    Article  CAS  PubMed  Google Scholar 

  26. Kanerva A et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275–280.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by National Institutes of Health and National Cancer Institute Grants R01 HL67962, R01 CA86881-01, R01 CA090547, R01 AG021875, P50 CA89019 and a research grant from Muscular Dystrophy Association.

Author information

Authors and Affiliations

  1. Division of Human Gene Therapy, Departments of Medicine, Pathology and Surgery, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL, USA

    H Wu, T Han, J T Lam, C A Leath, I Dmitriev, E Kashentseva & D T Curiel

  2. Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL, USA

    M N Barnes & R D Alvarez

Authors
  1. H Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J T Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C A Leath
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Dmitriev
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E Kashentseva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M N Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R D Alvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D T Curiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, H., Han, T., Lam, J. et al. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy. Gene Ther 11, 874–878 (2004). https://doi.org/10.1038/sj.gt.3302249

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302249

Keywords

This article is cited by

Search

Advanced search

Quick links